cancer. 1 , 2 Adjuvant endocrine therapy with tamoxifen and aromatase inhibitors is a mainstay of practice to reduce the risk of recurrence in patients with HR+ breast cancer. 3 Several clinical trials have demonstrated the benefit of extended adjuvant
Search Results
Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer
Saranya Chumsri, Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Katherine L. Pogue-Geile, Priya Rasgoti, Soonmyung Paik, Edith A. Perez, and E. Aubrey Thompson
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
-negative, advanced breast cancer were randomly assigned to first-line treatment with ribociclib or placebo with goserelin plus either a nonsteroidal AI or tamoxifen. 31 An improvement in PFS was seen with the addition of ribociclib (median PFS, 24 vs 13
Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer
receptor's ligand by blocking estrogen production via aromatase enzymatic inhibition. Tamoxifen is a nonsteroidal triphenylethylene derivative that acts as a SERM, with antagonist properties in mammary tissue. Tamoxifen has demonstrated efficacy and a
“Standard Care” in Cancer Clinical Trials: An Analysis of Care Provided to Women in the Control Arms of Breast Cancer Clinical Trials
Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall
-consistent/NCCN-nonconsistent trials involved adjuvant endocrine therapy; 2 used a gonadotropin-releasing hormone (GnRH) agonist and tamoxifen in premenopausal women, and 4 used tamoxifen in postmenopausal women. A GnRH agonist with tamoxifen is included in the AGO guidelines for
NCCN Guidelines Updates: Breast Cancer
Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar
the global MONALEESA-7 trial of almost 700 premenopausal or perimenopausal women rendered postmenopausal. 17 Patients had received no prior endocrine therapy for metastatic disease; by physician's choice they received an AI (mostly) or tamoxifen, plus
NCCN Task Force Report: Bone Health and Cancer Care
Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak
possible advantage of SERMs compared with estrogen therapy is the lack of early increase in coronary heart disease and a significant reduction in hormone receptor-positive breast cancer. Results of the ongoing STAR trial (Study of Tamoxifen and Raloxifene
Treatment of Metastatic Breast Cancer
William J. Gradishar
to the group of patients who had not been exposed to adjuvant tamoxifen. Dr. Gradishar questioned whether this outcome was clinically relevant. He stated that even though the SWOG trial may support administering combination therapy in first
NCCN News
predictor of breast cancer outcomes; however, several emerging biomarkers, such as the CYP 2D6 genotype to determine tamoxifen (Soltamox, AstraZeneca Pharmaceuticals, LP) efficacy, are also being researched extensively. “The efficacy of tamoxifen therapy
Adult Cancer Pain
Robert Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Craig D. Blinderman, Barry Boston, Charles Cleeland, Nessa Coyle, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Nora A. Janjan, Sloan Beth Karver, Michael H. Levy, Maureen Lynch, Natalie Moryl, Barbara A. Murphy, Suzanne A. Nesbit, Linda Oakes, Eugenie A. Obbens, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan Urba, and Sharon M. Weinstein
hepatic enzyme, CYP2D6. 29 , 30 Because data suggest that CYP2D6-inhibiting antidepressants increase risk of recurrence in patients with breast cancer treated with tamoxifen 31 , 32 (see Additional Therapies, page 1082), it is reasonable to assume that
Improving Care Coordination to Optimize Health Outcomes in Cancer Survivors
Linda Overholser and Carlin Callaway
.2019) recommend that women taking tamoxifen for invasive breast cancer should have an annual gynecologic assessment every 12 months. However, recommendations from the American College of Obstetricians and Gynecologists (ACOG) do not align with those from NCCN for
